US equities
|
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MU
$934.27
▼-4.98%
MSFT
$530.14
▼-0.16%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MU
$934.27
▼-4.98%
MSFT
$530.14
▼-0.16%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
BridgeBio Pharma, Inc. - Common Stock
(NQ:
BBIO
)
70.73
-0.09 (-0.13%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BridgeBio Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
October 29, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
October 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
October 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
October 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
October 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
October 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
October 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
October 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
October 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
September 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
September 09, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
September 02, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Participate in September Investor Conferences
September 01, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
August 31, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
August 30, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
August 26, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 03, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
July 02, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 01, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 28, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
